deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT04105010

Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)

A Phase I/II, Open-Label, Multicentre Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD4205 in Patients With Peripheral T Cell Lymphoma (PTCL)

Sponsor: Dizal Pharmaceuticals

Conditions Relapsed or Refractory Peripheral T Cell Lymphoma
Interventions golidocitinib
Updated 17 times since 2019 Last updated: Apr 3, 2025 Started: Sep 10, 2019 Primary completion: Oct 12, 2023 Completion: Feb 22, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04105010, this PHASE1/PHASE2 trial focuses on Relapsed or Refractory Peripheral T Cell Lymphoma and remains completed. Sponsored by Dizal Pharmaceuticals, it has been updated 17 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Oct 2019 – ~Sep 2020 · 11 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Feb 2022 · 8 months · monthly snapshot~Feb 2022 – ~Sep 2022 · 7 months · monthly snapshot~Sep 2022 – ~Jul 2023 · 10 months · monthly snapshot~Jul 2023 – ~Oct 2023 · 3 months · monthly snapshot~Oct 2023 – ~Feb 2024 · 4 months · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~May 2024 · 2 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. May 2025 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE2 → PHASE1/PHASE2

  3. Sep 2024 — May 2025 [monthly]

    Completed PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  5. May 2024 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 12 earlier versions

  1. Mar 2024 — May 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Feb 2024 — Mar 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Oct 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Jul 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  5. Sep 2022 — Jul 2023 [monthly]

    Recruiting PHASE2

  6. Feb 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  7. Jun 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

  8. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

    Phase: PHASE1_PHASE2 → PHASE2

  9. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  10. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE1_PHASE2

  11. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE1_PHASE2

  12. Oct 2019 — Sep 2020 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Sep 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dizal Pharmaceuticals
Data source: Dizal Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Beijing, China , Busan, South Korea , Changchun, China , Changsha, China , Chengdu, China , Chongqing, China , Daegu, South Korea , Dalian, China , East Melbourne, Australia and 27 more locations